Click play to watch the full presentation
Jason LaJoie PhD, Associate Director, Head of Lead Optimization at Alloy Therapeutics
Jason is the head of lead optimization platforms at Alloy Therapeutics. He leads development and execution of display-based protein engineering platforms to empower the Alloy ecosystem of partners in their drug discovery efforts. Jason is experienced in antibody library design, phage and yeast display screening, and next-generation sequencing, having previously worked for Compass Therapeutics & TCR² Therapeutics. He has a PhD in Chemical & Biological Engineering from the University of Wisconsin Madison.
Single domain antibodies (sdAbs) have emerged as ideal targeting arms in the fields of cell therapies and multispecific antibodies due to their small size, modularity, and ability to bind antigens with high affinity while avoiding VH/VL mispairing issues. Alloy Therapeutics has recently developed a semi-synthetic sdAb library platform built on stable human frameworks. This presentation will introduce the platform and share data for efficient phage display-based discovery of targeting arms with therapeutic applications.
